Cargando…

NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring

Detalles Bibliográficos
Autores principales:	Wang, Peng, Segal, Jeremy, Drazer, Michael W., Venkataraman, Girish, Arber, Daniel A., Gurbuxani, Sandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421992/ https://www.ncbi.nlm.nih.gov/pubmed/36051025 http://dx.doi.org/10.1002/jha2.445

Ejemplares similares

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
por: Alizad Ghandforoush, Nasrin, et al.
Publicado: (2016)

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
por: Forghieri, Fabio, et al.
Publicado: (2018)

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
por: Salipante, Stephen J., et al.
Publicado: (2014)

Detection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia
por: Tan, Angela YC, et al.
Publicado: (2008)

Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia
por: Lisi, Véronique, et al.
Publicado: (2022)

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
por: Emadi, Ashkan, et al.
Publicado: (2016)

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
por: Lesieur, Auriane, et al.
Publicado: (2020)

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2018)

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2019)

Acute Promyelocytic Leukemia or Acute Myeloid Leukemia with Mutated NPM1?
por: Cloobs-Venezia, Maximiliano, et al.
Publicado: (2022)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

The frequency of NPM1 mutations in childhood acute myeloid leukemia
por: Braoudaki, Maria, et al.
Publicado: (2010)

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
por: Chen, Yingyu, et al.
Publicado: (2020)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)

Identification of a novel NPM1 mutation in acute myeloid leukemia
por: Yao, Yiyi, et al.
Publicado: (2023)

Acute myeloid leukemia with concurrent NPM1 and RUNX1 mutations
por: Zuo, Zhuang, et al.
Publicado: (2023)

Isolated Mediastinal Myeloid Sarcoma after NPM1-Positive Pediatric Acute Myeloid Leukemia
por: Tüfekçi, Özlem, et al.
Publicado: (2019)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Identification of Two Novel NPM1 Mutations in Patients with Acute Myeloid Leukemia
por: Jeon, Yongbum, et al.
Publicado: (2013)

Recurrent SETD2 mutation in NPM1-mutated acute myeloid leukemia
por: Sun, Jiewen, et al.
Publicado: (2020)

Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2023)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
por: Onecha, Esther, et al.
Publicado: (2019)

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia
por: Lussana, Federico, et al.
Publicado: (2019)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
por: Chin, Lynn, et al.
Publicado: (2023)

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
por: Forghieri, Fabio, et al.
Publicado: (2019)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

NPM1A in Plasma is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
por: Sun, Chengming, et al.
Publicado: (2018)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
por: Chen, Xiaoyan, et al.
Publicado: (2021)

Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A
por: Jo, Su Yeon, et al.
Publicado: (2016)

A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)
por: Venanzi, Alessandra, et al.
Publicado: (2021)

Oncogenic role of lncRNA CRNDE in acute promyelocytic leukemia and NPM1-mutant acute myeloid leukemia
por: Ma, Xuefei, et al.
Publicado: (2020)

Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors
por: Roloff, Gregory W., et al.
Publicado: (2023)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
por: Mosna, Federico, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rklhst2rs7g8nv8a5rp93h7r16